Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The SARS-CoV-2 coronavirus, which causes COVID-19, uses its spike glycoprotein to enter host cells. The viral spike glycoprotein is the main target of host neutralizing antibodies that help to control SARS-CoV-2 infection and are important for the protection provided by vaccines.
Article activity feed
-
-
SciScore for 10.1101/2021.04.01.438120: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Cell lines: The wild-type SARS-CoV-2 S glycoprotein, with Asp 614, was inducibly expressed in Lenti-x-293T human female kidney cells from Takara Bio (Catalog #: 632180). Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Samples were Western blotted with 1:2,000 dilutions of rabbit anti-SARS-Spike S1, mouse anti-SARS-Spike S1, rabbit anti-SARS-Spike S2 or a 1:5,000 dilution of mouse anti-β-actin as the primary antibodies. anti-SARS-Spikesuggested: Noneanti-SARS-Spike S2suggested: Noneanti-β-actinsuggested: NoneHRP-conjug… SciScore for 10.1101/2021.04.01.438120: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Cell lines: The wild-type SARS-CoV-2 S glycoprotein, with Asp 614, was inducibly expressed in Lenti-x-293T human female kidney cells from Takara Bio (Catalog #: 632180). Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Samples were Western blotted with 1:2,000 dilutions of rabbit anti-SARS-Spike S1, mouse anti-SARS-Spike S1, rabbit anti-SARS-Spike S2 or a 1:5,000 dilution of mouse anti-β-actin as the primary antibodies. anti-SARS-Spikesuggested: Noneanti-SARS-Spike S2suggested: Noneanti-β-actinsuggested: NoneHRP-conjugated anti-rabbit or anti-mouse antibodies at a dilution of 1:5,000 were used as secondary antibodies in the Western blots. HRP-conjugatedsuggested: Noneanti-rabbitsuggested: Noneanti-mousesuggested: NoneBeads were washed three times and samples were Western blotted with a mouse anti-S1 antibody. anti-S1suggested: NoneExperimental Models: Cell Lines Sentences Resources Lenti-x-293T cells were grown in DMEM with 10% FBS supplemented with L-glutamine and Pen-Strep. Lenti-x-293Tsuggested: NoneOn the day prior to transfection, 293T cells were seeded in 6-well plates at a density of 1 x 106/well. 293Tsuggested: NonePurification of the S glycoproteins: To express the SARS-CoV-2 S glycoprotein for purification, 293T-S cells were induced with 1 µg/ml doxycycline for two days. 293T-Ssuggested: RRID:CVCL_LC70)Approximately 4 x 104 293T-ACE2 cells were then added to each well, and the cultures were maintained for an additional 24 h at 37°C before luciferase activity was measured. 293T-ACE2suggested: RRID:CVCL_YZ65)Software and Algorithms Sentences Resources The adjusted integrated volumes of S, S1 and S2 bands from unsaturated Western blots were calculated using Fiji ImageJ. ImageJsuggested: (ImageJ, RRID:SCR_003070)Neutralization activity was calculated from the reduction in luciferase activity compared to controls, using GraphPad Prism 8 (GraphPad Software Inc.). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-